Produção Nacional
Revisado por pares
OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway
2023; Multidisciplinary Digital Publishing Institute; Volume: 24; Issue: 24 Linguagem: Inglês
10.3390/ijms242417535
ISSN1661-6596
AutoresJoão Carlos Cardoso Alonso, Bianca Ribeiro de Souza, Ianny Brum Reis, Gabriela Cardoso de Arruda Camargo, Gabriela de Oliveira, Maria Izabel de Barros Frazão Salmazo, Juliana Mattoso Gonçalves, José Ronaldo de Castro Roston, Paulo Henrique Ferreira Cária, André da Silva Santos, Leandro Luiz Lopes de Freitas, Athanase Billis, Nelsón Durán, Wagner José Fávaro,
Tópico(s)Immunotherapy and Immune Responses
ResumoThis study assessed the safety and efficacy of OncoTherad
Referência(s)